Metabolic reprogramming of endothelial-related pathways in COVID-19 patients treated with hyperbaric oxygen therapy:
Natalia Jermakow1, Klaudia Brodaczewska2, Jacek Kot3
1Department of Hyperbaric Medicine, Military Institute of Medicine - National Research Institute, Szaserów 128, Warsaw, 04-141, Poland. njermakow@gmail.com.
Abstract:
COVID-19, caused by SARS-CoV-2, is increasingly recognized as a systemic disorder with inflammation, endothelial dysfunction, and metabolic perturbations. This study aimed to characterize metabolic changes in COVID-19 patients undergoing hyperbaric oxygen therapy (HBOT). The clinical trial was registered in EudraCT (2020-002722-90, 3 May 2020), prior to patient enrollment. Thirty hospitalized patients were enrolled and randomized; 28 (14 HBOT and 14 standard care) were included in the present metabolomics analysis. The HBOT group received five sessions at 2.5 ATA for 75 min. Serum metabolites were analyzed using high-resolution LC-MS. Significant changes were observed in metabolites related to arginine/NO metabolism, creatine turnover, phospholipid remodeling, and pterin derivatives. Pathway analysis highlighted the urea cycle, glycerophospholipid remodeling, niacin metabolism, and folate/pterin pathways. HBOT patients showed enhanced metabolic network connectivity. The findings suggest that HBOT induces systemic metabolic adaptations involving amino acid and lipid pathways, as well as redox-related metabolites, which may intersect with vascular and inflammatory regulation. (q < 0.05) (edges = 31 (vs. 10); P < 0.05, |r|>0.5).
More Related Videos
08:56Oxygen-Glucose Deprivation and Reoxygenation as an In Vitro Ischemia-Reperfusion Injury Model for Studying Blood-Brain Barrier Dysfunction
Published on: May 7, 2015
08:35Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
Published on: August 17, 2022
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Hypoxia
Types of Hypoxia
There are four primary types of hypoxia, each resulting from a different cause:
1. Anemic hypoxia: This type occurs due to insufficient oxygen delivery caused by a lack of red blood cells (RBCs) or RBCs with abnormal or...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Hypertension II: Pathophysiology
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
